Sequence: Stearyl-AGYLLGKLLOOLAAAALOOLL-NH2
| Experiment Id | EXP001410 |
|---|---|
| Paper | Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simula |
| Peptide | PepFect 14 (PF14) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Encoded by peptide:siRNA molar ratio (MR); typical MR30–MR40 |
| Rna Concentration | 50 nM (solid formulation tested at MR30); also 100 nM at MR40 |
| Mixing Ratio | PF14:siRNA molar ratio (MR) 20–40 screened; best MR depends on serum conditions |
| Formulation Format | Solid-dispersion formulation of PF14/siRNA nanocomplexes in mannitol (5%) |
| Formulation Components | PF14 + siRNA nanocomplexes dispersed in mannitol (5%) and dried (speed-vac) then reconstituted |
| Size Nm | 113.00 |
| Zeta Mv | 22.74 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HEK 293 luciferase-stable (human embryonic kidney) |
| Animal Model | |
| Administration Route | |
| Output Type | Luciferase knockdown after reconstitution of dried powder |
| Output Value | |
| Output Units | |
| Output Notes | Mannitol (5%) solid-dispersion PF14/siRNA maintained RNAi activity comparable to freshly prepared complexes after reconstitution. |
| Toxicity Notes | |
| Curation Notes |